Substance / Medication

Mupirocin

Overview

Active Ingredient
mupirocin
RxNorm CUI
42372

Indications

Staphylococcus aureus (S. aureus) Streptococcus pyogenes (S. pyogenes) Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to susceptible isolates ofand.

Labeler: Redpharm DrugUpdated: 2026-02-03T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
0
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Mupirocin resistance in Staphylococcus aureus: A systematic review and meta-analysis.
Dadashi Masoud, Hajikhani Bahareh, Darban-Sarokhalil Davood et al. · J Glob Antimicrob Resist · 2020
PMID: 31442624Meta-Analysis
Mupirocin-resistantin Africa: a systematic review and meta-analysis.
Shittu Adebayo O, Kaba Mamadou, Abdulgader Shima M et al. · Antimicrob Resist Infect Control · 2018
PMID: 30147868Meta-AnalysisFull text (PMC)
Clinical Effectiveness of Mupirocin for Preventing Staphylococcus aureus Infections in Nonsurgical Settings: A Meta-analysis.
Nair Rajeshwari, Perencevich Eli N, Blevins Amy E et al. · Clin Infect Dis · 2016
PMID: 26503378Meta-Analysis
Long-Term Safety of Buttonhole Cannulation and Efficacy of Mupirocin Prophylaxis.
Agarwal Arnav, Nesrallah Gihad · Contrib Nephrol · 2015
PMID: 26283561Meta-Analysis
Impact of mupirocin resistance on the transmission and control of healthcare-associated MRSA.
Deeny Sarah R, Worby Colin J, Tosas Auguet Olga et al. · J Antimicrob Chemother · 2015
PMID: 26338047Meta-AnalysisFull text (PMC)
Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA.
Poovelikunnel T, Gethin G, Humphreys H · J Antimicrob Chemother · 2015
PMID: 26142407Meta-Analysis
Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review.
van Rijen Miranda M L, Bonten Marc, Wenzel Richard P et al. · J Antimicrob Chemother · 2008
PMID: 18174201Meta-Analysis
Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers.
van Rijen Miranda, Bonten Marc, Wenzel Richard et al. · Cochrane Database Syst Rev · 2008
PMID: 18843708Meta-AnalysisFull text (PMC)
Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis.
Kallen Alexander J, Wilson Chad T, Larson Robin J · Infect Control Hosp Epidemiol · 2005
PMID: 16417031Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mupirocin (substance)
SNOMED CT
387397004
UMLS CUI
C0085259
RxNorm CUI
42372
Labeler
Redpharm Drug

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.